The collaboration focuses on strengthening diagnostic and treatment capabilities, aligning clinical practices, and enhancing professional training in lung, prostate, and hematologic cancers.

The partnership will include hospital-based programs such as scientific forums, targeted training, and practice-alignment initiatives aimed at improving early detection, supporting evidence-based decision-making, and promoting more consistent care pathways.

Cancer remains a major public health challenge in Vietnam. According to Globocan, the country recorded an estimated 180,480 new cancer cases and 120,184 cancer- deaths in 2022, underscoring the need to improve early diagnosis, multidisciplinary care, and timely access to treatment.

Among priority areas, lung cancer, prostate cancer, and hematologic malignancies continue to present clinical challenges. In lung cancer, some patient groups remain underdiagnosed due to limited awareness and testing, while access to targeted therapies is still developing. Prostate cancer incidence is increasing, but access to advanced diagnostics and newer treatment options remains uneven.

In hematology, improving diagnostic capacity and standardizing care pathways are seen as important steps toward earlier intervention and better long-term outcomes for conditions such as multiple myeloma and leukemia. Addressing these issues requires coordinated efforts across the healthcare system, including expanded clinical collaboration and knowledge sharing.

Under the agreement, Johnson & Johnson Vietnam will support a range of professional activities, including scientific conferences, research and publication workshops, continuing medical education (CME) programs, and specialized seminars covering lung, prostate, and hematologic cancers. Training activities will also be extended to healthcare professionals in the northern and north central regions.

K Hospital will lead implementation, hosting and delivering the programs while integrating standardized care pathways into clinical practice and expanding training through its regional network.

Upendra Patkie, General Manager of Johnson & Johnson Innovative Medicine Vietnam, shared: “K Hospital plays a central role in transferring oncology knowledge, sharing guidelines, and ensuring that clinical practices are adapted and shared across Vietnam. By formalizing this collaboration, Johnson & Johnson is working at the heart of Vietnam’s cancer care system, where global evidence is translated into locally relevant care pathways. This MoU enables us to support earlier detection, consistent multidisciplinary decisions, and stronger alignment with evidence‑based treatments, so that progress in cancer care reaches patients more reliably”.